Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology
Manuscript NO: 37366
Title: Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
Reviewer's code: 02876269
Reviewer's country: Italy
Science editor: Li-Jun Cui
Date sent for review: 2017-12-18
Date reviewed: 2017-12-20
Review time: 2 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In the article "Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?" the Authors describe the possible role of copeptin as molecular marker for ADPKD. The topic is very interesting because little is known about the use of biomarkers for the diagnosis/prognosis of ADPKD. Unfortunately, copeptin expression is affected by different environment factors, rending hard the use of this molecule as efficient biological marker. Copertin, likely, could be used as a possible marker in patient selection for the treatment with Tolvaptan. There are things that can be improved. Minor Points: - In the legend of Fig. 1 the last part of the sentence is lost. "Figure adapted from…???". - Chapter "Synthesis, function and degradation of copeptin", the table cited in the sentence "As summarised in Table 2, the precursor peptide…" is wrong, therefore must be substituted with table 1. - In the

Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Chapter "Advantages and disadvantages of copeptin measurement in the laboratory", Authors describe possible disadvantages for the copeptin measurement in clinical laboratories mainly in terms of costs. In my opinion, this description is incorrect because, as underline the Authors, there are insufficient clinical evidence for the use of copeptin as ADPKD marker. Therefore, the clinical use of copeptin is still too far. - Are there evidences of copeptin plasma level variations in ADPKD patients treated with Tolvaptan? The reduction or the slowed increase in copeptin plasma levels could indicate a "good" response to Tolvaptan treatment.

Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology
Manuscript NO: 37366
Title: Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
Reviewer's code: 03475636
Reviewer's country: United States
Science editor: Li-Jun Cui
Date sent for review: 2018-01-04
Date reviewed: 2018-01-07
Review time: 3 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is well written review on serum copeptin and autosomal dominant polycystic kidney disease. However, I have a few suggestions to improve this review. 1. In introduction, please also include for information regarding use of Copeptin measurement in various other clinical indications, e.g., including the diagnosis of diabetes insipidus and the monitoring of sepsis and cardiovascular diseases. 2. Case control study by Corradi et al is an important one, I agree. The reference for citation #28 is not correct; should be Corradi et al, not Zittema et al. Corradi et al. recently demonstrated that glomerular filtration affects copeptin to a greater extent rather than its correlation to AVP [28] 3. Suggest discussing the findings by Nakajima et al. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). PMID: 25715868

Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology
Manuscript NO: 37366
Title: Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
Reviewer's code: 02855928
Reviewer's country: Japan
Science editor: Li-Jun Cui
Date sent for review: 2018-01-04
Date reviewed: 2018-01-11
Review time: 6 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[Y] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Some biomarkers are crucial for the diagnosis of ADPKD and the prediction of prognosis. Expression of copeptin is 'multifactorial' (i.e., some situations have some effects on the result). This point should be mentioned.

Baishideng Publishing Group

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology
Manuscript NO: 37366
Title: Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
Reviewer's code: 00468214
Reviewer's country: Italy
Science editor: Li-Jun Cui
Date sent for review: 2018-01-04
Date reviewed: 2018-01-15
Review time: 11 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[Y] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The paper is well written and the bibliography adeguate. It clearly explains uses and future developments of copeptin as possible biomarker in order to evaluate therapy response and to stratify patients with ADPKD (to early individuate those with a higher risk of ESKD). Minor language polishing required.